Clinical Trial: A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07008118) titled 'A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms' on May 29.

Brief Summary: This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.

Study Start Date: July 30

Study Type: INTERVENTIONAL

Condition: Myeloproliferative Neoplasms

Intervention: DRUG: INCA035784

INCA035784 will be administered at protocol defined dose.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Incyte Corporation

Disclaimer: Curated by HT Syndication....